CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. [electronic resource]
Producer: 20140320Description: 866-77 p. digitalISSN:- 1552-4604
- Adolescent
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Brentuximab Vedotin
- Cross-Over Studies
- Cytochrome P-450 CYP3A -- metabolism
- Cytochrome P-450 CYP3A Inhibitors
- Drug Interactions
- Feces -- chemistry
- Female
- Hematologic Neoplasms -- metabolism
- Humans
- Immunoconjugates -- administration & dosage
- Ketoconazole -- administration & dosage
- Ki-1 Antigen -- immunology
- Male
- Midazolam -- administration & dosage
- Middle Aged
- Oligopeptides -- metabolism
- Rifampin -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.